Tarlatamab plus durvalumab improves survival in extensive-stage small cell lung cancer
Tarlatamab plus durvalumab improves survival in extensive-stage small cell lung cancer
Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer
Lifileucel plus pembrolizumab shows durable responses in first-line advanced melanoma
Short course durvalumab remodels the tumour immune microenvironment in early stage triple negative breast cancer
Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma
ESMO 2026: Advances in NMIBC and MIBC
UV1 vaccine combination shows no significant PFS improvement in BRCA wild type recurrent ovarian cancer
Camupepimut shows early disease free survival signal in resected KRAS mutated pancreatic cancer
Sacituzumab govitecan combination shows promising activity in first line metastatic urothelial cancer
Tarlatamab's role in SCLC
WCLC 2026: Lung cancer research highlights
Harnessing AI and data to predict, personalise and transform cancer care